Quotient doubles formulation capacity; WuXi raising $80M for manufacturing;

> Quotient Clinical is doubling its formulation development capacity with the construction of a new, 8,000-square-foot manufacturing facility. News

> WuXi PharmaTech ($WX) is selling a 6% stake in its SynTheAll manufacturing unit for $80 million. Story

> Catalent says it has resolved some issues at a North Carolina plant that surfaced in a routine FDA inspection. More

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.